G1 Therapeutics (GTHX) to Release Earnings on Wednesday

G1 Therapeutics (NASDAQ:GTHX) will post its quarterly earnings results after the market closes on Wednesday, August 7th. Analysts expect G1 Therapeutics to post earnings of ($0.73) per share for the quarter.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.05. On average, analysts expect G1 Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Shares of GTHX traded down $0.70 on Monday, hitting $23.81. The company’s stock had a trading volume of 3,410 shares, compared to its average volume of 302,998. The business has a fifty day moving average of $26.47. G1 Therapeutics has a fifty-two week low of $13.87 and a fifty-two week high of $69.57. The stock has a market capitalization of $918.39 million, a price-to-earnings ratio of -9.57 and a beta of 2.66.

Several equities analysts recently issued reports on the company. ValuEngine upgraded G1 Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. Cowen restated a “buy” rating on shares of G1 Therapeutics in a research note on Tuesday, June 18th. BidaskClub upgraded G1 Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, June 24th. Finally, Zacks Investment Research cut G1 Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $60.43.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Further Reading: How a Put Option Works

Earnings History for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.